EC Ophthalmology

Keratitis represents the fifth most common cause of blindness worldwide [1] and a leading cause of irreversible visual impairment [2]. No age group is immune to it [3]. In the adult population older than 40 years 3.372 million suffered from moderate or severe deterioration of vision due to corneal opacity, as was estimated in 2020 by Wang., et al [4]. Early recognition and prompt treatment initiation are key to sight preserving in order to achieve the best outcomes in patients with keratitis.

1. Cabrera-Aguas M., et al. “Infectious keratitis: A review”. Clinical and Experimental Ophthalmology 5 (2022): 543-562.
2. Ung L., et al. “Infectious corneal ulceration: a proposal for neglected tropical disease status”. Bulletin of the World Health Organization 12 (2019): 854-856.
3. Cabrera-Aguas M and Watson SL. “Updates in diagnostic imaging for infectious keratitis: A review”. Diagnostics (Basel)21 (2023): 3358.
4. Wang EY., et al. “Global trends in blindness and vision impairment resulting from corneal opacity 1984-2020: A meta-analysis”. Ophthalmology8 (2023): 863-871.
5. Khoo P., et al. “Bacterial eye infections”. In: Rezaei N., editor. Encyclopedia of Infection and Immunity. Elsevier Oxford, UK (2022): 204-218.
6. Ting DSJ., et al. “Diagnostic armamentarium of infectious keratitis: A comprehensive review”. The Ocular Surface 23 (2022): 27-39.
7. Grzybowski A., et al. “The use of povidone-iodine in ophthalmology”. Current Opinion in Ophthalmology 1 (2018): 19-32.
8. Reibaldi M., et al. “The effectiveness of 0.6% povidone iodine eye drops in reducing the conjunctival bacterial load and needle contamination in patients undergoing anti-VEGF intravitreal injection: A prospective, randomized study”. Journal of Clinical Medicine7 (2019): 1031.
9. National Center for Biotechnology Information. PubChem Compound Summary for CID 410087, Povidone iodine (2023).
10. Lepelletier D., et al. “Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus decolonization”. Antimicrobial Agents and Chemotherapy9 (2020): e00682-20.
11. Bai D., et al. “Comparing the efficacy of chlorhexidine and povidone-iodine in preventing surgical site infections: A systematic review and meta‐analysis”. International Wound Journal (2023).
12. Soleimani M., et al. “In praise of povidone-iodine application in ophthalmology”. Survey of Ophthalmology 8 (2023): S0039-6257(23)00143-1.
13. Edington M., et al. “Virucidal benefits of povidone-iodine use on the ocular surface: a review”. BMJ Open Ophthalmology1 (2020): e000509.
14. Cheung D., et al. “Epidemic kerato-conjunctivitis-do outbreaks have to be epidemic?” Eye3 (2003): 356-363.
15. Akanuma M. “[Evaluation of disinfectant against adenovirus by real-time polymerase chain reaction]”. Nippon Ganka Gakkai Zasshi5 (2007): 384-390.
16. Yates KA., et al. “The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types”. Journal of Ocular Pharmacology and Therapeutics 2 (2019): 132-136.
17. Trinavarat A and Atchaneeyasakul L-O. “Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study”. Journal of Ocular Pharmacology and Therapeutics 1 (2012): 53-58.
18. Özen Tunay Z., et al. “Povidone iodine in the treatment of adenoviral conjunctivitis in infants”. Cutaneous and Ocular Toxicology 1 (2015): 12-15.
19. Yazar H., et al. “The effects of povidone iodine (pH 4.2) on patients with adenoviral conjunctivitis”. Journal of the Pakistan Medical Association 8 (2016): 968-970.
20. Shorter E., et al. “Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study”. The Ocular Surface 4 (2019): 828-832.
21. Altan-Yaycioglu R., et al. “Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates”. International Journal of Ophthalmology 9 (2019): 1420-1425.
22. Kawana R., et al. “Inactivation of human viruses by povidone-iodine in comparison with other antiseptics”. Dermatology1 (1997): 29-35.
23. Benevento WJ., et al. “The sensitivity of Neisseria gonorrhoeae, Chlamydia trachomatis, and herpes simplex type II to disinfection with povidone-iodine”. American Journal of Ophthalmology 3 (1990): 329-333.
24. Wutzler P., et al. “Virucidal and chlamydicidal activities of eye drops with povidone-iodine liposome complex”. Ophthalmic Research 2-3 (2000): 118-125.
25. Wutzler P., et al. “Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine”. Antiviral Research 2 (2002): 89-97.
26. Reimer K., et al. “Antimicrobial effectiveness of povidone-iodine and consequences for new application areas”. Dermatology1 (2002): 114-120.
27. Sauerbrei A and Wutzler P. “Virucidal efficacy of povidone-iodine-containing disinfectants”. Letters in Applied Microbiology 51 (2010): 158-163.
28. Ito H., et al. “Outbreak of highly pathogenic avian influenza in Japan and anti-influenza virus activity of povidone-iodine products”. Dermatology1 (2006): 115-118.
29. Numazaki K and Asanuma H. “Inhibitory effect of povidone-iodine for the antigen expression of human cytomegalovirus”. In Vivo3 (1999): 239-241.
30. Kaplan JC., et al. “Inactivation of human immunodeficiency virus by Betadine”. Infection Control 10 (1987): 412-414.
31. Harbison MA and Hammer SM. “Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine”. Journal of Acquired Immune Deficiency Syndromes 1 (1989): 16-20.
32. Shimakoshi Y., et al. “A micro-suspension-test for evaluation of disinfectants against human immunodeficiency virus”. Kansenshogaku Zasshi5 (1995): 532-538.
33. Eggers M., et al. “Povidone-iodine hand wash and hand rub products demonstrated excellent in vitro virucidal efficacy against Ebola virus and modified vaccinia virus Ankara, the new European test virus for enveloped viruses”. BMC Infectious Diseases 15 (2015): 375.
34. Wada H., et al. “Relationship between virucidal efficacy and free iodine concentration of povidone-iodine in buffer solution”. Biocontrol Science 1 (2016): 21-27.
35. Sokal DC and Hermonat PL. “Inactivation of papillomavirus by low concentrations of povidone-iodine”. Sexually Transmitted Diseases 1 (1995): 22-24.
36. Matsuhira T., et al. “Evaluation of four antiseptics using a novel murine norovirus”. Experimental Animals 1 (2012): 35-40.
37. Kariwa H., et al. “Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents”. Dermatology1 (2006): 119-123.
38. Kampf G., et al. “Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents”. Journal of Hospital Infection 3 (2020): 246-251.
39. Wang X and Jacobs DS. “An update on the initial treatment of Acanthamoeba keratitis”. International Ophthalmology Clinics2 (2022): 101-110.
40. Hale LM. “The treatment of corneal ulcer with povidone-iodine (Betadine)”. North Carolina Medical Journal2 (1969): 54-56.
41. Kadam SP. “Application of betadine (povidone iodine) to infected corneal ulcer”. Indian Journal of Ophthalmology5-6 (1987): 135-136.
42. Hadipour Jahromy M., et al. “Effectiveness of povidone-iodine 1% eye drop on Streptococcus pneumoniae and Escherichia coli induced-keratitis in mice”. Galen Medical Journal 8 (2019): e1161.
43. Isenberg SJ., et al. “Prospective, randomized clinical trial of povidone-iodine 1.25% solution versus topical antibiotics for treatment of bacterial keratitis”. American Journal of Ophthalmology 176 (2017): 244-253.
44. Pedrotti E., et al. “The role of topical povidone-iodine in the management of infectious keratitis: a pilot study”. Journal of Clinical Medicine 3 (2022): 848.
45. Bordin P. “Corneal ulcer treated with 0.66% nanoemulsion povidone-iodine: a case report”. American Journal of Case Reports 21 (2020): e919822.
46. Bordin P. “Low-Concentration (0.66%) povidone iodine treatment of a corneal ulcer in a rheumatoid arthritis patient”. American Journal of Case Reports 22 (2021): e928748.
47. Grzybowski A and Kanclerz P. “Povidone-iodine can be used in the treatment of microbial keratitis”. Survey of Ophthalmology6 (2019): 891-892.
48. Ndoye Roth PA., et al. “Problème diagnostique et thérapeutique de la kératite mycosique en zone intertropicale. Intérêt de l'usage local de la polividone iodée [Fungal keratitis in an intertropical area: diagnosis and treatment problems. Advantage of local use of polyvidone iodine]”. Journal Français d'Ophtalmologie 8 (2006): e19.
49. Ramatchandirane B., et al. “Successful management of fungal keratitis caused by multidrug-resistant Cladosporium species using povidone-iodine: a case report”. Cornea1 (2022): 10-97.
50. Acosta A., et al. “Managing a pigmented corneal ulcer in a 58-year-old patient”. Cureus10 (2023): e46850.
51. Padzik M., et al. “Effect of povidone iodine, chlorhexidine digluconate and toyocamycin on amphizoic amoebic strains, infectious agents of Acanthamoeba keratitis - a growing threat to human health worldwide”. Annals of Agricultural and Environmental Medicine 4 (2018): 725-731.
52. Muthukumar V., et al. “Efficacy of off-label anti-amoebic agents to suppress trophozoite formation of Acanthamoeba on non-nutrient agar Escherichia coli plates”. Microorganisms 10.8 (2022): 1642.
53. Azzopardi M., et al. “Diagnosis of Acanthamoeba keratitis: Past, present and future”. Diagnostics16 (2023): 2655.
54. Feghi M., et al. “Investigating the effect of eye drops based on iodine nanoparticles in the treatment of corneal ulcers in rabbit eyes”. Journal of Ophthalmic Inflammation and Infection 1 (2023): 47.
55. Oliverio GW., et al. “Safety and tolerability of an eye drop based on 0.6% povidone-iodine nanoemulsion in dry eye patients”. Journal of Ocular Pharmacology and Therapeutics 2 (2021): 90-96.